Welcome to our dedicated page for DNA X SEC filings (Ticker: SONM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DNA X's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DNA X's regulatory disclosures and financial reporting.
DNA X, Inc. filed Amendment No. 1 to its annual report to update Part III disclosures on directors, executive compensation, security ownership, related‑party transactions, and auditor fees, and to add certain exhibits and officer certifications.
The filing details leadership changes, including the former CEO’s resignation and a cash severance of $855,000, plus accelerated option vesting and COBRA coverage. It also outlines a membership interest purchase from DNA Holdings for 223,201 redeemable shares, and a related unsecured $1,200,000 note bearing 10% interest, convertible into common stock at an initial price of $5.50 per share, with protective adjustments. As of April 21, 2026, there were 1,488,268 shares outstanding, and the aggregate market value of non‑affiliate shares was about $12.6 million as of June 30, 2025.
DNA X, Inc. filed an 8-K announcing that its Audit Committee dismissed Baker Tilly US, LLP as independent registered public accounting firm and approved the engagement of TAAD LLP for the fiscal year ending December 31, 2026.
Baker Tilly’s reports on the 2024 and 2025 financial statements were generally unqualified but the 2025 report included a statement raising substantial doubt about the company’s ability to continue as a going concern. The company also disclosed a continuing material weakness in internal control over financial reporting related to insufficient technical accounting expertise for complex, non-routine transactions, which has not yet been remediated.
The company reported no disagreements with Baker Tilly on accounting, disclosure, or audit scope, and no other reportable events beyond the previously disclosed material weakness. Baker Tilly provided a letter to the SEC agreeing with the company’s description of these matters, filed as Exhibit 16.1.
DNA X, Inc. (formerly Sonim Technologies) files its annual report describing its pivot from rugged mobile devices to a crypto trading platform operating at www.dnax.us. The company now focuses on automated cryptocurrency trading, swapping and planned products such as crypto lending and staking-like fee products.
The filing highlights intense competition with much larger exchanges, heavy reliance on third‑party contractors and a highly uncertain, fast‑evolving regulatory landscape for digital assets in the U.S. and abroad. DNA X is not yet profitable, and its auditor raises substantial doubt about its ability to continue as a going concern without additional funding.
The report emphasizes significant risks from cryptocurrency price volatility, potential classification of certain tokens or staking services as securities, and complex privacy, sanctions, consumer protection and anti‑money‑laundering rules. As of June 30, 2025, non‑affiliate equity market value was about $12.6 million, and 1,488,268 common shares were outstanding as of March 27, 2026.
DNA X, Inc. reported full-year 2025 results showing a net loss of $20.7 million, improved from $33.6 million in 2024, with no revenue from continuing operations. Continuing-operations net loss was $8.0 million, driven mainly by $5.4 million in general and administrative expenses and higher interest and other expenses.
The company completed its strategic pivot from mobile devices to cryptocurrency trading. It acquired the DNA X trading platform in December 2025 and sold its mobile device design and manufacturing business to NEXA for $15 million in January 2026. Most proceeds repaid debt and other obligations, with remaining cash earmarked to support the trading business.
As of December 31, 2025, cash and cash equivalents were $1.3 million, total assets $43.9 million, total liabilities $50.6 million, and stockholders’ deficit $8.0 million. The company rebranded to DNA X, Inc., operates a DeFi-based automated trading platform, and experienced leadership changes, including the CEO’s resignation and appointment of its Executive Chairman as acting CEO.
DNA X, Inc. filed an amended current report to clarify the accounting treatment of its acquisition of DNA X LLC. The company had purchased 100% of the membership interests in DNA X LLC for 223,201 shares of its common stock, representing 19.99% of its outstanding common shares at issuance.
After a detailed financial analysis, DNA X determined that this transaction does not involve a “significant amount of assets” for purposes of Item 2.01 of the Exchange Act rules. As a result, the company concluded the transaction did not trigger Item 2.01 disclosure and will not provide the financial statements or pro forma financial information that were referenced in its earlier report.
DNA X, Inc. large shareholder DNA Holdings Venture Inc. filed an initial ownership report showing direct holdings of 223,201 shares of Common Stock. This Form 3 establishes that DNA Holdings Venture Inc. is a more than ten percent owner of DNA X, Inc. as of the reported date.
DNA Holdings Venture Inc., Scott Walker, and Brock Pierce reported a significant stake in DNA X, Inc. on Schedule 13D. They beneficially own 223,201 shares of common stock, representing about 19.99% of DNA X’s outstanding shares based on 1,116,286 shares outstanding as of December 15, 2025.
The stake stems from a membership interest purchase where DNA X acquired 100% of DNA X LLC for 223,201 shares, alongside a $1,200,000 convertible promissory note that is convertible at $5.50 per share starting six months after issuance. DNA Holdings also received a put option tied to DNA X LLC’s trading volume or revenue performance before June 30, 2026.
So long as DNA Holdings owns at least 5% of DNA X’s common stock, it can designate one officer and one board nominee, and it has agreed to vote its shares in favor of a specified asset purchase agreement under an irrevocable proxy through the earlier of January 15, 2026 or that agreement’s termination.
DNA X, Inc. shareholder Laurence W. Lytton filed an amended Schedule 13G reporting a significant passive stake in the company’s common stock. As of the event date, he beneficially owned 148,290 shares, representing 9.96% of the 1,488,268 shares outstanding.
Lytton reports sole voting and dispositive power over 109,402 shares and shared power over 38,888 shares. The filing notes additional warrants to purchase 22,222 shares are excluded because they are subject to a 4.99% beneficial ownership limitation. He certifies the holdings are not intended to change or influence control of DNA X, Inc.
1 Main Capital Management and related reporting persons report that they now beneficially own 0 shares, or 0.0%, of Sonim Technologies common stock as of December 31, 2025. All four reporting entities list zero sole or shared voting and dispositive power over Sonim shares. The filing confirms they own 5 percent or less of the class and certifies the position is not held to change or influence control of Sonim Technologies.